Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
absent, accommodate, acid, adjudication, advocacy, afflicted, Alex, Alexion, ALXN, amino, Aon, Appl, artemisinin, ATM, attenuated, BDNF, Beal, bioengineered, BioSource, blinded, bond, breath, Bristol, broadly, Brown, Budget, budgetary, burden, burn, CAG, Carolina, cast, caution, cessation, chose, closer, commodity, commuting, concomitant, concomitantly, conflict, conventional, coordinating, Cornell, COU, coupled, CRADA, CRF, cultural, culture, CV, CyNCh, Cystadane, cysteine, debilitating, defraud, degeneration, dehydration, delineated, depth, diagnosed, dietary, disagree, disrupted, dossier, Doude, Dutch, egg, elevated, encompassing, Enobia, equate, Erbez, error, exhaled, extracellular, extracted, extraordinary, facial, Fanconi, fibrotic, formulae, fraudulent, Genzyme, Georgia, glutathione, GSH, Hambrecht, Hawaii, hedge, Henk, hereditary, histological, Honolulu, Hospitalier, hour, hub, hypothetical, hypothyroidism, idle, imprisonment, indebted, infused, insert, instance, intake, intervention, intracellular, inventory, irrespective, Ithaca, Jazz, Keller, knowingly, language, Laval, leadership, Levtchenko, link, lump, macroeconomic, mailing, main, malaria, markedly, McGill, MINE, miscommunication, misdiagnosed, modification, Montreal, MOU, mouse, multicenter, myopathy, Myozyme, NAS, nausea, negating, Nephrol, nerve, neuron, neuronal, neurotrophic, NIDDK, night, nighttime, NOL, odor, oxidized, parasite, parasitic, pathophysiology, payor, PDUFA, pegylated, pension, percentile, photophobia, poor, Portability, powder, PPI, precursor, preparatory, prerequisite, preset, pretax, privacy, PROCYSBI, Promedior, proportional, quantifiable, Quebec, Quist, Radford, ranked, RaptorCaresTM, RDT, recapture, red, referral, regimen, registry, relocate, relocation, remuneration, renal, rescuing, residence, respiratory, Rett, robust, rotten, scenario, scheme, SCRI, Seattle, shift, Shortly, skilled, skipping, sleep, smell, Smith, socially, solvency, span, Squib, Statute, Stewart, strict, struggle, Suboptimal, Sunshine, tablet, thirst, thrive, Troostwijk, tube, UBC, unaffected, underway, uninterrupted, Universit, Universitaire, unrealized, unsatisfied, unusual, upheld, urgent, urination, version, visible, voluntarily, vomiting, Wall, Wanger, weather, webcasting, widespread, worst, worth, XBRL
Removed:
accountant, activate, acute, AMPA, annum, antagonist, assign, attestation, beneficially, bid, binding, block, buy, call, certified, collaborating, complexity, concept, Craig, dedicated, delivering, diminish, document, dosed, efficient, Elan, examination, expired, expiring, feet, formed, fourth, furniture, glutamate, impede, inconclusive, internally, internet, la, licensee, LP, mg, multiplying, neurologic, OTC, partnering, partnership, penny, peptide, Plant, play, preclude, produced, promoting, proof, recruiting, reincorporated, removed, repaid, replicate, reserved, revert, select, shared, show, sought, square, studying, subtype, unacceptable, unmet
Filing tables
Filing exhibits
Related press release
Horizon Pharmaceutical similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 No. 333-179215, No. 333-162430, No. 333-166249, No. 333-168966, No. 333-162374 and No. 333-173720 and Form S-8 No. 333-173719, No. 333-166813, No. 333-163124, No. 333-151859, No. 333-141738, No. 333-138368, No. 333-118729, No. 333-103129, No. 333-98245 and No. 333-48088 of Raptor Pharmaceutical Corp. of our reports dated November 13, 2012, relating to the consolidated financial statements and financial statement schedule of Raptor Pharmaceutical Corp. and its subsidiaries (which report expresses an unqualified opinion and includes an explanatory paragraph regarding uncertainty about Raptor Pharmaceutical Corp.'s ability to continue as a going concern), and the effectiveness of internal control over financial reporting as of August 31, 2012, which appear in Raptor Pharmaceutical Corp's Annual Report on Form 10-K for the year ended August 31, 2012.
/s/ Burr Pilger Mayer, Inc.
Burr Pilger Mayer, Inc.
San Francisco, California
November 13, 2012